Pilot Trials in Nephrology: Establishing a BASE for Large-Scale Randomized Trials
Authors: Brendon L. Neuen, Vlado Perkovic
Journal: Journal of the American Society of Nephrology (2019)

Randomized controlled trials remain the only way to reliably assess moderate treatment effects because they are the study design that best safeguards against bias due to residual or unmeasured confounding.1 However, there have been fewer randomized trials in nephrology to guide treatment decisions than most other internal medical specialties.2 As a result, many commonly used treatments remain untested and the benefits and harms of these interventions remain uncertain. Increasing the quality and quantity of trials is crucial to achieving better kidney care and has been identified as a priority for the international nephrology community.3 The design and conduct of kidney trials can be challenging for many reasons. Sample size and power calculations are underpinned by a number of assumptions which may not hold true despite best estimates. Because kidney failure typically develops over a long period of time, studies seeking to identify effects on this outcome require long follow-up and, until recently,4 there has been little consensus among investigators, funders, and regulatory agencies about other appropriate kidney function–based outcomes. Compared with the general population, medication dosing, tolerance, and adherence often differs in patients with CKD who have a high burden of illness and rate of adverse events.1 Recruitment for kidney trials is also often challenging due to limitations in coordinated global trial networks and infrastructure. The net result is threefold. Firstly, most trials in kidney disease have been too small or short to detect moderate-sized treatment effects on patient-level outcomes that could be expected from any single intervention5. Secondly, the outcomes which have been reported have been too varied and frequently not aligned with patient or caregiver priorities: a shortcoming which is (rightfully) being addressed by the SONG (Standardized Outcomes in Nephrology) initiative.6 Thirdly, many well designed trials set out with good intentions, but are unsuccessful due to unanticipated challenges in recruitment, adherence, outcome rates, or other factors. Identifying and addressing potential scientific, operational, and implementation challenges is crucial to ensuring that a large-scale outcome trial provides a reliable answer to the question being studied. Carefully conducted and reported pilot trials are an important way to ensure such challenges and potential strategies to address them are “road tested,” which can then be adjusted before the main trial, and provide invaluable information that can be instructive for future studies. The BASE (Bicarbonate Administration to Stabilize eGFR) pilot trial is one such example, which paves the way for a definitive large-scale outcome trial. Previous small trials have collectively suggested that bicarbonate supplementation may prevent progression of CKD, but these studies have been too small, have commonly been single center, and/or have had other limitations that mean they cannot adequately guide treatment.7 In this edition of JASN, Raphael et al.8 conducted a multicenter pilot study to assess the tolerability, safety, and pharmacodynamic profile of two doses of sodium bicarbonate over 28 weeks. The investigators randomized 194 patients with stage 3 CKD to two different dosages of bicarbonate (0.5 or 0.8 meq/kg lean body wt per day) or matching placebo and found that both bicarbonate dosages were well tolerated, with no difference in gastrointestinal symptoms or hospitalizations compared with placebo. Moreover, BP and body weight were similar at 28 weeks, with no increased use of antihypertensives or diuretics in participants treated with bicarbonate. The authors concluded that higher-dose bicarbonate might be preferred in a large outcome trial, based on similar tolerability, lower urinary ammonium excretion and higher serum bicarbonate. The BASE trial therefore provides important data to help guide dose selection in future trials of bicarbonate supplementation in CKD. Other recent examples of valuable and informative pilot trials include BLOCADE (β-Blockers to Lower Cardiovascular Dialysis Events) and PHASE (Pilot Trial of Hemodialysis Patients undergoing Aldosterone Antagonism with Eplerenone). BLOCADE was a multicenter feasibility trial that aimed to assess the proportion of patients receiving hemodialysis who could tolerate carvedilol at a dosage of 6.25 mg twice daily during the run-in period.9 The trial was unable to recruit its planned sample size, suggesting that a subsequent larger outcome trial was unlikely to be feasible. The PHASE trial tested whether eplerenone was noninferior to placebo in patients receiving hemodialysis for the outcome of discontinuation due to hyperkalemia or hypotension.10 The trial showed no significant difference in discontinuation rates, suggesting a large outcome trial could be feasible. The results of the PHASE trial have been critical in establishing the ACHIEVE (Aldosterone Blockade for Health Improvement Evaluation in ESKD) trial, which aims to recruit approximately 2750 patients receiving dialysis to assess the effect of spironolactone on a primary outcome of cardiovascular death or hospitalization for heart failure. Some challenges, however, cannot be anticipated. The RADAR (Reducing Residual Albuminuria in Subjects with Diabetes and Nephropathy with Atrasentan) trial helped to successfully define the optimal dose of the endothelin-receptor antagonist atrasentan to lower albuminuria without increasing the risk of fluid retention.11 The subsequent outcome trial, SONAR (Atresentan and Renal Events in Patients with Type 2 Diabetes and CKD), ultimately showed that atresentan can slow the progression of kidney disease due to type 2 diabetes, but was still challenged by lower-than-expected event rates.12 Although it was not possible in this case, pilot trials can also help to set realistic expectations regarding outcome parameters, as well as recruitment and retention. As a stretch goal, it has been proposed that 30% of all patients with CKD should be enrolled in randomized controlled trials by 2030.13 Pilot trials are a crucial study design to help achieve this goal. It is important that the kidney community, funding agencies, and nephrology journals prioritize such studies as valuable contributions. Disclosures Dr. Neuen is supported by an Australian National Health and Medical Research Council Postgraduate Scholarship; the John Chalmers PhD Scholarship from The George Institute for Global Health; a University Postgraduate Award from University of New South Wales Sydney; and an Oxford Australia Clarendon Scholarship from the University of Oxford. He has received travel support from Janssen. Dr. Perkovic reports receiving research support from the Australian National Health and Medical Research Council (Senior Research Fellowship and Program Grant); serving on steering committees for AbbieVie, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Janssen, Novo Nordisk and Pfizer; serving on advisory boards and/or speaking at scientific meetings for AbbVie, Astellas, AstraZeneca, Bayer, Baxter, Bristol-Myers Squibb, Boehringer Ingelheim, Durect, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Novo Nordisk, Pfizer, Pharmalink, Relypsa, Roche, Sanofi, Servier, and Vitae; and receiving personal fees for consulting and scientific presentations related to canagliflozin from Mitsubishi Tanabe and Mundipharma.